MedMira Reports Year End Results

HALIFAX, Nov. 28, 2011 /CNW/ - MedMira Inc., ("MedMira") (TSXV: MIR) (NASDAQ: MMIRF), a developer of rapid diagnostic technology and solutions, reported today on its financial results for the year ended July 31, 2011.

"MedMira experienced a decrease in sales in North America this year, which impacted overall sales revenue.  However, the Company made significant advancements in the US, namely with the USD$2,278,192 US Army contract which extends over 32 months. We believe this contract gives the Company a solid foundation for future growth," said Hermes Chan, CEO, MedMira Inc.  "The decline in North American sales was further offset by the positive results we have seen in Asia. Our strategic partner in China, Triplex International Biosciences Co. Ltd. (Triplex) has made significant progress in building market presence and winning new business.  Their business development team continues to expand market reach and build on MedMira's number one ranking in a China Center for Disease Control evaluation to capitalize on new business opportunities in both the public and private sectors."

Chan continued, "MedMira continues to pursue new business using its strategic partnership model, which enables the Company to have a presence in markets around the world and direct access to local, national, and regional health regulators and key customers.  While we have made progress in many of these international markets this year, the timelines to complete sales remain unpredictable."

Financial Highlights

  • The Company recorded revenue from product sales of $909,869 as compared to $1,073,175 for the same period last year, a decrease of approximately 15%.
  • The revenue decrease was primarily attributable to the Company's decreased sales in North America.  
    The Company recorded revenue from North American product sales of $540,340 as compared to $876,478 for the same period last year.
  • Sales in Asia Pacific increased from $41,529 in 2010 to $178,403 in 2011.
  • Gross profit for the year was $415,955 or 45.7% compared to $735,023 or 68.5% in the prior year. Prior year gross profit was higher than expected due to a one-time reduction in accrued expenses.
  • For the year ended July 31, 2011 operating expenses were $2.3 million compared to $3.0 million last year. The decrease in operating expenses resulted from continued financial efficiencies realized from consolidation of facilities and tighter fiscal controls.

About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible future growth and new business opportunities.  Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE MEDMIRA INC.

For further information:

MedMira Contact:
Andrea Young, Corporate Communications
Tel: 902-450-1588
Email: ayoung@medmira.com

Profil de l'entreprise

MEDMIRA INC.

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.